Peer-reviewed veterinary case report
Genes linked to beta blocker response in dogs with heart failure
By Lanfear, David E et al.·Published in Discovery medicine·2011·Heart and Vascular Institute, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Genome-wide approach to identify novel candidate genes for beta blocker response in heart failure using an experimental model.
- Species:
- dog
Plain-English summary
A group of dogs with heart failure was treated with beta blockers to see how their hearts responded to the medication. Researchers found three specific genes that seemed to be linked to better heart function after treatment. By comparing the gene activity in dogs that received beta blockers to those that did not, they discovered that the treated dogs showed improvements in heart size and pumping ability. This research could help identify why some dogs respond better to certain heart medications than others.
People also search for: dog heart failure treatment · beta blockers for dogs · heart medication response in dogs
Abstract
BACKGROUND: We explored use of a canine model of heart failure (HF) for pharmacogenomic discovery, specifically analyzing response to beta blockers (BB). METHODS: Dogs with HF that received BB (n=39) underwent genome-wide genotyping to test the association with changes in left ventricular (LV) volume and ejection fraction after treatment. Resulting candidate genes underwent RNA quantification in cardiac tissue from normal (n=5), placebo-HF (n=5), and BB-HF (n=7) dogs. RESULTS: Three markers met whole-genome significance for association with improved LV end-systolic volume after BB therapy (each p<5 x 10(-7)). RNA quantification of three candidate genes near these markers -- GUCA1B, RRAGD, and MRPS10 -- revealed that gene expression levels in BB-HF dogs were between that of placebo-HF dogs and normal dogs. CONCLUSION: Genome-wide pharmacogenomic screening in a canine model of HF suggests 3 novel BB response candidate loci. This approach is adaptable to discovering mechanisms of action for other drug therapies, and may be a useful strategy for identifying candidate genes for drug response in the pre-clinical setting.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21524389/